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Abstract
Background—Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) 
have previously been suggested as oncologic prognostication markers. These are associated with 
malnutrition and inflammation, and hence, may provide benefit in predicting mortality among 
hemodialysis patients.
Methods—Among 108,548 incident hemodialysis patients in a large U.S. dialysis organization 
(2007–2011), we compared the mortality predictability of NLR and PLR with baseline and time-
varying covariate Cox models using the receiver operating characteristic curve (AUROC), net 
reclassification index (NRI), and adjusted R2.
Results—During the median follow-up period of 1.4 years, 28,618 patients died. Median 
(interquartile range) NLR and PLR at baseline were 3.64 (2.68–5.00) and 179 (136–248), 
respectively. NLR was associated with higher mortality, which appeared stronger in the time-
varying vs. baseline model. PLR exhibited a J-shaped association with mortality in both models. 
NLR provided better mortality prediction in addition to demographics, comorbidities, and serum 
albumin; ΔAUROC and NRI for 1-year mortality (95%CI) were 0.010 (0.009–0.012) and 6.4% 
(5.5%–7.3%), respectively. Additionally, adjusted R2 (95%CI) for the Cox model increased from 
0.269 (0.262–0.276) to 0.283 (0.276–0.290) in the non-time-varying model and from 0.467 
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(0.461–0.472) to 0.505 (0.500–0.512) in the time-varying model. There was little to no benefit of 
adding PLR to predict mortality.
Conclusions—High NLR in incident hemodialysis patients predicted mortality, especially in the 
short-term period. NLR, but not PLR, provided additional benefit in predicting mortality along 
with demographics, comorbidities, and serum albumin, and should be included in prognostication 
approaches.
Keywords
hemodialysis; chronic hemodialysis; end stage kidney disease; neutrophil; platelet; lymphocyte; 
mortality; nutrition; inflammation
Introduction
Low-grade systemic and persistent inflammation may play an important role in the 
development and progression of various chronic conditions and diseases such as obesity, 
diabetes, atherosclerotic cardiovascular disease, cancer, chronic obstructive lung disease, and 
chronic kidney disease (CKD).1–3 Among patients with end-stage renal disease (ESRD), 
chronic inflammation is highly prevalent and associated with adverse clinical outcomes 
including cardiovascular disease and all-cause death.4–8 Inflammation in this context is 
attributed to various underlying factors including the uremic milieu, infections, decreased 
clearance of proinflammatory cytokines, volume overload, endotoxinemia, oxidative stress, 
carbonyl stress, and dialysis-related factors.9–12 A recent study found increased arterial wall 
inflammation even in non-dialysis patients with CKD,13 which may explain the 
cardiovascular risk associated with CKD.14 Inflammation can also interact with malnutrition 
and lead to wasting and derangements in protein–energy nutritional status, i.e., protein-
energy wasting (PEW), resulting in the excessively high mortality in the dialysis population.
10,12
 C-reactive protein, interleukin-6, and tumor necrosis factor-α are among representative 
inflammatory markers, but their measurements are costly and/or inaccessible in current 
clinical practice.
The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), readily 
available biomarkers calculated from complete blood count, are closely associated with 
inflammation and were originally suggested as oncologic prognostic factors.15,16 
Subsequently higher values in NLR and PLR have been linked to greater inflammatory 
status and worse prognosis among patients with various disease conditions including 
cardiovascular disease,17 chronic obstructive pulmonary disease,18 liver cirrhosis,19 and 
CKD.20 Furthermore, recent studies have indicated that NLR and PLR were associated with 
inflammation and may predict mortality among hemodialysis patients as well,21–26 but their 
small study sample sizes make it difficult to draw a definite conclusion regarding their 
detailed associations with mortality and comparative usefulness in mortality-predictability 
when compared to other clinically accessible markers related to CKD. To address this 
knowledge gap, we studied a 5-year large national cohort of incident hemodialysis patients 
in the United States and investigated the relationship of NLR and PLR with all-cause 
mortality.
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METHODS
This study was approved by the Institutional Review Committees of the Los Angeles 
Biomedical Research Institute at Harbor-UCLA, University of California Irvine Medical 
Center, and the University of Washington, with the exemption of obtaining written consent 
given the large sample size, anonymity of the patients studied, and nonintrusive nature of the 
research.
Patients
We retrospectively extracted, refined, and examined data from all ESRD patients aged ≥18 
years who initiated dialysis from January 1, 2007 to December 31, 2011and who received 
dialysis treatment in one of the facilities operated by a large dialysis organization in the 
United States.27 Patients were followed up from the of first date dialysis until death, kidney 
transplantation, loss to follow-up, or the date of final follow-up assessment for all patients 
(i.e., December 31, 2011). The follow-up time was divided into patient-quarters (i.e., 91-day 
periods from the first date of dialysis).
Out of the 156,229 patients who were initially treated with conventional hemodialysis, we 
excluded 30,493 patients who did not receive dialysis treatment for ≥60 consecutive days, 
13,719 patients who were ever treated with other modalities (e.g., less frequent 
hemodialysis, frequent hemodialysis, nocturnal hemodialysis, home hemodialysis, or 
peritoneal dialysis), 2,593 and 579 patients with missing data or NLR values >14 (i.e., >99.5 
percentile), respectively on complete blood count markers. We also excluded 297 patients 
without data on serum albumin, phosphorus, and alkaline phosphatase (ALP) at baseline 
(Figure 1).
Demographic, clinical, and laboratory measures
Information on death, race/ethnicity, primary insurance, access type, the presence of 
comorbidities, and laboratory variables were obtained from the administrative electronic 
database of the dialysis provider. To minimize measurement variability, all repeated 
measures for each patient were averaged within each patient-quarter and then used in all 
analyses. The averaged values during the first patient-quarter (the first 91-days of dialysis) 
served as baseline data.
Blood samples were drawn using uniform techniques in all dialysis clinics and were 
transported to the central laboratory in Deland, Florida, typically within 24 hours. All 
laboratory values were measured by automated and standardized methods. Most laboratory 
values were measured monthly with the exception of serum ferritin and intact parathyroid 
hormone (PTH) that were measured at least quarterly. Hemoglobin was measured at least 
monthly in essentially all patients and weekly to bi-weekly in most patients. NLR was 
calculated using percent neutrophil divided by percent lymphocyte whereas PLR was 
calculated using platelet count divided by lymphocyte count. Single-pool Kt/V (spKt/V) was 
calculated using urea kinetic modeling equations.28
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Statistics
Differences in baseline characteristics between two groups were compared by standardized 
differences, of which 0.8, 0.5, and 0.2 in absolute value were considered large, medium, and 
small differences, respectively, due to the relatively large sample size of this study.29,30 NLR 
and PLR, the primary exposures of this study, were categorized into 6 groups (<2.0, 2.0–
<3.0, 3.0–<4.0, 4.0–<5.0, 5.0–<6.0, and ≥6.0; and <100, 100–<150, 150–<200, 200–<250, 
250–<300, and ≥300, respectively). Their associations with each patient characteristic were 
evaluated using a non-parametric trend test. Logistic regression was used to identify the 
predictors of high NLR or PLR using arbitrary cut offs (i.e., ≥4.0 and ≥200, respectively). 
Cox regression models with baseline (non-time-varying) or time-varying covariates were 
used to estimate associations with all-cause mortality. Models were examined with three 
levels of adjustment as follows:
I. Unadjusted model that included NLR or PLR;
II. Case-mix adjusted models that included the above plus age, sex, race and 
ethnicity, primary insurance, 12 comorbidities as in Table 1, vascular access type, 
body mass index (BMI), and spKt/V; and
III. MICS adjusted models which included all of the covariates in the case-mix 
model plus nine laboratory variables related to the malnutrition-inflammation-
cachexia complex syndrome (MICS) [i.e., white blood cell (WBC) count, 
hemoglobin, serum albumin, creatinine, albumin-corrected calcium, phosphorus, 
iron saturation, total bicarbonate, ALP, total iron binding capacity (TIBC), and 
natural log-transformed intact PTH and ferritin].
Time-varying covariates included vascular access type, BMI, spKt/V, and laboratory 
variables. In order to compare mortality-predictabilities of NLR and PLR with those of 
albumin and ALP, the mortality risk was estimated according to the deciles of each variable. 
The reason for selecting serum albumin and ALP for the comparison is that both indices 
have been consistently and linearly associated with mortality among hemodialysis patients.
31,32
 Serum albumin is a representative MICS marker while ALP is not in the realm of 
MICS but is an abnormality observed in ESRD as a part of CKD-MBD. The area under the 
receiver operating characteristic curve (AUROC) and net reclassification index (NRI) were 
examined for 1-year mortality using logistic regression with different sets of variables at 
baseline. Additionally, explained variation (i.e., adjusted R2, a transformation of Royston 
and Sauerbrei’s D measure of discrimination of a survival model)33 was evaluated in both 
time-varying and non-time-varying Cox models to compare the overall performance measure 
across models. The frequency of missing data was low [<1% for BMI and most laboratory 
tests, except for ferritin (1.2%), nPCR (1.5%), and creatinine (4.6%)], and mean imputation 
was used in all regression analyses. All analyses were conducted using STATA MP version 
13.1 (StataCorp, College Station, TX).
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RESULTS
Baseline demographic, clinical and laboratory characteristics
Baseline characteristics were compared between included and excluded patients and we 
found that the 108,548 included patients were less likely to be Caucasian; and were more 
likely to have a CV catheter as their initial vascular access. Compared to the 47,681 
excluded patients who lacked NLR or PLR data, included patients had higher hemoglobin, 
lower white blood cell count, lower neutrophil, higher lymphocyte, higher albumin, higher 
creatinine, higher phosphorus, higher intact PTH, higher TIBC, lower ferritin, lower 
bicarbonate, and higher prevalence of hypertension, diabetes, and congestive heart failure at 
baseline (Supplemental Table 1). The mean±SD age of the final study cohort was 63±15 
years of whom 56% were male, 47% were Caucasian, 15% were Hispanic, and 59% were 
diabetic (Table 1). The median (interquartile range [IQR]) of NLR and PLR were 3.64 (2.68, 
5.00) and 179 (136, 248), respectively. As NLR values increased, the absolute lymphocyte 
count decreased while the absolute counts of white blood cell and neutrophil increased. The 
absolute platelet count values were not different between the high and low NLR groups. 
Patients with higher NLR values were more likely to be older and Caucasian, but less likely 
to be African American. Likewise, As PLR values increased, the absolute lymphocyte count 
decreased while the absolute neutrophil and platelets counts increased. There were no 
meaningful differences in demographics, comorbid conditions, and the absolute white blood 
cell count between the high and low NLR groups.
Biochemical Associations of NLR and PLR
After adjustment for case-mix variables, baseline laboratory variables associated with higher 
NLR (vs. below the median) included lower levels of hemoglobin, albumin, creatinine, 
albumin-corrected calcium, phosphorus, intact PTH, TIBC, and iron saturation and higher 
levels of WBC, ALP, ferritin, and bicarbonate (Supplemental Table 4). PLR exhibited 
similar association patterns for those laboratory variables except for WBC, where lower 
levels of WBC were associated with higher PLR. Calcium and phosphorus levels were not 
associated with PLR.
Associations of NLR and PLR with all-cause mortality
Out of 108,548 patients, a total of 28,618 patients died during the median follow-up period 
of 1.4 years (IQR, 0.6 to 2.5 years) with an incidence rate of 15.6 (95%CI, 15.4 to 15.7) per 
100 patient-years. Baseline characteristics of the study cohort stratified by 6 NLR groups 
and 6 PLR groups are presented in Supplemental Table 2 and Supplemental Table 3, 
respectively. Unadjusted non-time-varying (baseline) Cox models demonstrated that higher 
NLR levels were linearly associated with all-cause mortality risk. Those who had greater 
NLR experienced incrementally higher mortality, which was robust against adjustments for 
case-mix and MICS characteristics (Ptrend<0.001 for all; Figure 1A and Supplemental Table 
5). Similarly, the time-varying covariate model demonstrated incremental mortality risk 
across greater NLR irrespective of adjustment model, which appeared stronger than those 
observed in the baseline model (Ptrend<0.001 for all; Figure 1B). When compared to NLR of 
2.0 to <3.0, a hazard ratio (HR) of ≥6.0 NLR was 1.94 (95%CI, 1.87 to 2.02) and 4.54 
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(95%CI, 4.34 to 4.75) in the baseline vs. the time-varying covariate Cox model with 
adjustment for case-mix variables, respectively.
Baseline PLR exhibited a J-shaped association with all-cause mortality in all adjustment 
models; the lowest risk was observed in the second lowest group (i.e., PLR 100 to <150), 
and higher levels were associated with all-cause mortality risk (Figure 1C and Supplemental 
Table 5). As with NLR, the time-varying covariate model exhibited a consistent yet stronger 
association between PLR and all-cause mortality, when compared to the baseline model 
(Figure 1D). Using PLR of 100 to 150 as reference, a case-mix adjusted hazard ratio (HR) of 
≥300 PLR was 1.43 (95%CI, 1.37 to 1.48) and 2.95 (95%CI, 2.82 to 3.09) in the baseline vs. 
time-varying covariate Cox model, respectively.
Mortality Predictability Comparisons of Selected Laboratory Variables
In order to evaluate the clinical usefulness in predicting mortality, we compared the hazard 
ratios (Figure 2) of deciles among serum albumin, serum ALP, NLR, and PLR, and then 
compared AUROC (Table 2), NRI (Table 2 and Supplemental Table 6–12), and adjusted R2 
(Table 3) among lymphocyte, neutrophil, and platelet counts in addition to those variables 
above.
Serum albumin appeared to be the strongest predictor of all-cause mortality in both the non-
time-varying and time-varying Cox models with adjustment for the case-mix variables 
(Figure 2), with the greatest AUROC and the highest NRI for 1-year mortality (Table 2). 
Adjusted R2 of serum albumin was also highest in both the non-time-varying and time-
varying Cox model (Table 3). Baseline serum ALP and neutrophil, when compared to 
lymphocyte and platelet, showed higher AUROC, NRI, and adjusted R2, and neutrophil 
showed a higher adjusted R2 than serum ALP in the time-varying model. However, NLR and 
the combination of neutrophil and lymphocyte demonstrated equivalent mortality 
predictability, which was better than serum ALP especially in the time-varying model. 
Neither PLR nor the combination of platelet and lymphocyte provided clinically relevant 
gain in these indices. When baseline NLR was added into the model including the case-mix 
variables and serum albumin, ΔAUROC and NRI was 0.010 (95%CI, 0.009 to 0.012) and 
6.4% (95%CI, 5.5% to 7.3%), respectively, which was greater than those observed with 
serum ALP and PLR. It also increased adjusted R2 from 0.269 (0.263, 0.277) to 0.286 
(0.279, 0.293) in the non-time-varying model and from 0.484 (0.479, 0.491) to 0.510 (0.504, 
0.516) in the time-varying model.
Sensitivity analysis including patients with baseline NLR values >14 (i.e., >99.5 percentile) 
showed consistent results with a slight attenuation in the mortality predictability of NLR 
(data not shown)
DISCUSSION
We demonstrated that high NLR was a strong predictor of all-cause death among 
hemodialysis patients. Patients with malnutrition and inflammation were likely to have high 
NLR. Baseline NLR was incrementally associated with higher mortality and provided 
modest benefit to mortality prediction in addition to the case-mix variables and serum 
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albumin. The NLR-mortality association was more pronounced in the time-varying model, 
suggesting a stronger association of NLR with short-term mortality than with long-term 
mortality. The mortality predictability of NLR appeared to be similar to or better than that of 
serum ALP or the combination of neutrophil and lymphocyte. Although PLR was associated 
with MICS variables, it exhibited a J-shaped association with mortality, and there was little, 
if any, improvement in mortality-predictability by adding either PLR or the combination of 
platelet and lymphocyte to the model including the case-mix variables and serum albumin.
Previous studies of dialysis patients demonstrated that both NLR and PLR had moderate 
correlations with direct inflammatory markers such as C-reactive protein, interleukin-6, and 
tumor necrosis factor-α21,26,34 and that higher NLR and PLR values were associated with 
greater mortality.23,25 Some studies also suggested that PLR may have a stronger correlation 
with inflammation and better mortality-predictability than NLR.25,26 However, these studies 
had small sample sizes (<200 patients), and hence, were susceptible to over-adjustment in 
multivariable analyses. Additionally, it remained difficult to judge the benefit of adding NLR 
or PLR as a new predictor to an existing model because these studies did not evaluate 
performance measures such as AUROC, NRI, and adjusted R2. The large sample size of our 
cohort allowed us to rigorously adjust for clinically relevant factors and to evaluate several 
model performances, all of which supported the better mortality-predictability of NLR than 
PLR.
Serum albumin has good correlations with NLR34 because inflammatory status leads to high 
NLR by increasing neutrophils and decreasing lymphocytes, and because it also results in 
low serum albumin levels by downregulating albumin gene transcription.35–38 Additionally, 
both serum albumin and lymphocyte count have been used as indices of nutritional status. 
Thus, serum albumin and NLR share common pathophysiological rationale for survival 
prediction. However, a previous study highlighted the lack of correlation between total 
lymphocyte count and nutritional status in the elderly39 while recent randomized clinical 
trials demonstrated that protein supplementation increased serum albumin levels, which may 
explain the stronger association of serum albumin with survival than NLR in our study. 
Nevertheless, NLR modestly improved mortality prediction in addition to the case-mix 
variables and serum albumin. This additional benefit of adding NLR might be related to its 
shorter time to response to inflammation than serum albumin; neutrophils are rapidly 
released from the bone marrow into the bloodstream with a short half-life (~6–8 hours)40 
whereas serum albumin decreases through reduced synthesis rate and has a longer half-life 
(~19–21 days).
We acknowledge several limitations in this study. First, due to the observational nature of 
our study, we cannot prove causality between NLR or PLR and death, nor exclude the 
possibility of residual confounding. Second, the administrative database from a large dialysis 
organization does not enable us to individually identify specific condition(s) for high NLR 
or PLR, such as infection, malnutrition, central venous catheter, stress, metabolic syndrome, 
and atherosclerosis. Third, there are currently no established reference ranges for NLR and 
PLR in the general population or the dialysis population although a previous study of 
healthy individuals reported lower NLR values (2.5th–97.5th percentiles, 0.8–3.5)41 than 
those in our study. However, our survival analyses showed a linear association between 
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higher NLR and higher mortality without clear thresholds indicating its optimal ranges. 
Finally, we included exclusively incident hemodialysis patients, and it remains unclear 
whether our findings can be extrapolated to prevalent hemodialysis patients or peritoneal 
dialysis patients. Nevertheless, our study is the largest study of hemodialysis patients 
evaluating model performance measures of NLR and PLR, and both non-time-varying and 
time-varying models yielded consistent results.
In conclusion, a high NLR in incident HD patients predicted mortality, especially in the 
short-term period, and provided modest benefit to predict mortality in addition to 
demographics, comorbidities, and serum albumin. PLR demonstrated a weaker association 
with mortality, and there was small or virtually no gain in mortality-predictability. NLR, 
together with serum albumin, may be useful as a surrogate of nutritional and inflammatory 
status in both clinical and epidemiological research settings given that it is readily available 
without additional cost.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Mortality risk associated with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-
lymphocyte ratio (PLR) after initiating dialysis among 108,548 incident hemodialysis 
patients (2007–2011) in the (A and C) baseline and (B and D) time-varying Cox models 
with three-level hierarchical adjustments, respectively.
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Figure 2. 
Case-mix adjusted all-cause mortality hazard ratios of deciles of (A) baseline and (B) time-
varying serum albumin, serum alkaline phosphatase (ALP), neutrophil-to-lymphocyte ratio 
(NLR), and platelet-to-lymphocyte ratio (PLR) among 108,548 patients. Only the deciles of 
serum albumin were ordered in reverse (i.e., the highest on the left and the lowest on the 
right) for the comparison with the other indices.
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Table 2
Area under receiver operating characteristic curve (AUROC) and net reclassification index (NRI) for 1-year 
mortality by adding baseline levels of serum albumin, serum alkaline phosphatase (ALP), lymphocyte, 
neutrophil, platelet, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in addition 
to the case-mix variables.
AUROC ΔAUROC NRI
Case-mix variables 0.701 (0.696, 0.705) Reference Reference
     plus Serum albumin 0.743 (0.738, 0.747) 0.042 (0.039, 0.045) 16.1% (14.9%, 17.2%)
     plus Serum alkaline phosphatase 0.713 (0.709, 0.717) 0.012 (0.011, 0.014) 5.8% (5.0%, 6.5%)
     plus Lymphocyte 0.706 (0.702, 0.710) 0.005 (0.004, 0.007) 5.4% (4.6%, 6.2%)
     plus Neutrophil 0.708 (0.704, 0.713) 0.008 (0.006, 0.009) 5.6% (4.7%, 6.5%)
     plus Platelet 0.702 (0.697, 0.706) 0.001 (0.000, 0.002) 1.6% (1.0%, 2.1%)
     plus Neutrophil and Lymphocyte 0.716 (0.712, 0.721) 0.016 (0.014, 0.018) 9.3% (8.3%, 10.3%)
     plus Platelet and Lymphocyte 0.706 (0.702, 0.710) 0.005 (0.004, 0.007) 5.2% (4.4%, 6.1%)
     plus NLR 0.719 (0.715, 0.724) 0.019 (0.017, 0.021) 9.5% (8.5%, 10.5%)
     plus PLR 0.703 (0.699, 0.707) 0.002 (0.002, 0.003) 2.4% (1.8%, 3.1%)
Case-mix variables + serum albumin See above See above See above
     plus Serum alkaline phosphatase 0.747 (0.743, 0.751) 0.004 (0.004, 0.005) 2.8% (2.3%, 3.4%)
     plus Lymphocyte 0.747 (0.743, 0.751) 0.004 (0.003, 0.005) 4.1% (3.3%, 4.8%)
     plus Neutrophil 0.745 (0.741, 0.749) 0.002 (0.002, 0.003) 2.9% (2.2%, 3.6%)
     plus Platelet 0.744 (0.740, 0.749) 0.002 (0.001, 0.002) 1.9% (1.3%, 2.6%)
     plus Neutrophil and Lymphocyte 0.751 (0.747, 0.755) 0.008 (0.007, 0.010) 6.3% (5.5%, 7.2%)
     plus Platelet and Lymphocyte 0.748 (0.743, 0.752) 0.005 (0.004, 0.006) 4.8% (4.0%, 5.5%)
     plus NLR 0.753 (0.749, 0.757) 0.010 (0.009, 0.012) 6.4% (5.5%, 7.3%)
     plus PLR 0.744 (0.740, 0.748) 0.001 (0.001, 0.001) 1.0% (0.6%, 1.5%)
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Table 3
Adjusted R2 in the non-time-varying and time-varying Cox model by adding serum albumin, serum alkaline 
phosphatase (ALP), lymphocyte, neutrophil, platelet, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-
lymphocyte ratio (PLR) in addition to the case-mix variables.
Non-time-varying model Time-varying model
Case-mix variables 0.203 (0.196, 0.210) 0.307 (0.302, 0.315)
    plus serum Alb 0.269 (0.263, 0.277) 0.484 (0.479, 0.491)
    plus ALP 0.218 (0.210, 0.225) 0.329 (0.324, 0.336)
    plus Lymphocyte 0.211 (0.204, 0.216) 0.331 (0.326, 0.337)
    plus Neutrophil 0.218 (0.213, 0.226) 0.379 (0.373, 0.385)
    plus Platelet 0.204 (0.196, 0.210) 0.308 (0.302, 0.315)
    plus Neutrophil and Lymphocyte 0.229 (0.222, 0.236) 0.406 (0.401, 0.411)
    plus Platelet and Lymphocyte 0.211 (0.205, 0.217) 0.335 (0.329, 0.341)
    plus NLR 0.230 (0.224, 0.237) 0.398 (0.393, 0.403)
    plus PLR 0.207 (0.201, 0.213) 0.333 (0.328, 0.340)
Case-mix variables + serum Alb
    plus ALP 0.278 (0.272, 0.287) 0.487 (0.482, 0.493)
    plus Lymphocyte 0.276 (0.270, 0.282) 0.490 (0.485, 0.497)
    plus Neutrophil 0.276 (0.270, 0.284) 0.503 (0.500, 0.509)
    plus Platelet 0.273 (0.267, 0.280) 0.484 (0.480, 0.489)
    plus Neutrophil and Lymphocyte 0.284 (0.276, 0.292) 0.513 (0.507, 0.518)
    plus Platelet and Lymphocyte 0.277 (0.271, 0.286) 0.490 (0.486, 0.496)
    plus NLR 0.286 (0.279, 0.293) 0.510 (0.504, 0.516)
    plus PLR 0.270 (0.261, 0.278) 0.488 (0.483, 0.493)
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